Risk of COVID-19 and major adverse clinical outcomes among people with disabilities in South Korea

被引:12
作者
Choi, Jae Woo [1 ]
Han, Euna [2 ]
Lee, Sang Gyu [3 ]
Shin, Jaeyong [3 ]
Kim, Tae Hyun [4 ]
机构
[1] Natl Hlth Insurance Serv, Hlth Insurance Res Inst, Community Care Res Ctr, Gangwon, South Korea
[2] Yonsei Univ, Coll Pharm, Yonsei Inst Pharmaceut Sci, Incheon, South Korea
[3] Yonsei Univ, Coll Med, Dept Prevent Med, Seoul, South Korea
[4] Yonsei Univ, Dept Hosp Adm, Grad Sch Publ Hlth, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Disability; COVID-19; Major adverse clinical outcomes; Korean; HEALTH-CARE;
D O I
10.1016/j.dhjo.2021.101127
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Evidence regarding the risk of coronavirus disease (COVID-19) and the major adverse clinical outcomes of COVID-19 among people with disabilities (PwDs) is scarce. Objective: This study investigated the association of disability status with the risk of severe acute res-piratory syndrome coronavirus 2 (SARS-CoV-2) test positivity and the risk of major adverse clinical outcomes among participants who tested positive for SARS-CoV-2. Methods: This study included all patients (n = 8070) who tested positive for SARS-CoV-2 and individuals without COVID-19 (n = 121,050) in South Korea from January 1 to May 30, 2020. The study variables included officially registered disability status from the government, SARS-CoV-2 test positivity, and major adverse clinical outcomes of COVID-19 (admission to the intensive care unit, invasive ventilation, or death). Results: The study participants included 129,120 individuals (including 7261 PwDs), of whom 8070 (6.3%) tested positive for SARS-CoV-2. After adjusting for potential confounding factors, PwDs had an increased risk of SARS-CoV-2 test positivity compared with people without disabilities (odds ratio [OR]: 1.36, 95% confidence interval [CI]: 1.24-1.48). Among participants who tested positive for SARS-CoV-2, PwDs were associated with an increased risk of major adverse clinical outcomes from COVID-19 compared to those without disabilities (OR: 1.43, 95% CI: 1.11-1.86). Conclusions: PwDs had an increased risk of COVID-19 and major adverse clinical outcomes of COVID-19 compared with people without disabilities. Given the higher vulnerability of PwDs to COVID-19, tailored policy and management to protect against the risk of COVID-19 are required. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页数:7
相关论文
共 28 条
[1]  
[Anonymous], 2018, NUMB REG DIS PEOPL S
[2]  
[Anonymous], 1980, International classification of impairments, disabilities, and handicaps
[3]   The COVID-19 response must be disability inclusive [J].
Armitage, Richard ;
Nellums, Laura B. .
LANCET PUBLIC HEALTH, 2020, 5 (05) :E257-E257
[4]   Communication Services and Supports for Individuals With Severe Disabilities: Guidance for Assessment and Intervention [J].
Brady, Nancy C. ;
Bruce, Susan ;
Goldman, Amy ;
Erickson, Karen ;
Mineo, Beth ;
Ogletree, Bill T. ;
Paul, Diane ;
Romski, Mary Ann ;
Sevcik, Rose ;
Siegel, Ellin ;
Schoonover, Judith ;
Snell, Marti ;
Sylvester, Lorraine ;
Wilkinson, Krista .
AJIDD-AMERICAN JOURNAL ON INTELLECTUAL AND DEVELOPMENTAL DISABILITIES, 2016, 121 (02) :121-138
[5]  
Centers for Disease Control and Prevention, 2020, Ctr. Dis. Control Prev.
[6]   Social inequities in the distribution of COVID-19: An intra-categorical analysis of people with disabilities in the US [J].
Chakraborty, Jayajit .
DISABILITY AND HEALTH JOURNAL, 2021, 14 (01)
[7]   Psychiatric disorders and suicide risk among adults with disabilities: A nationwide retrospective cohort study [J].
Choi, Jae Woo ;
Lee, Kang Soo ;
Han, Euna .
JOURNAL OF AFFECTIVE DISORDERS, 2020, 263 :9-14
[8]  
Hollis ND, 2020, DISABIL HEALTH J, V2021
[9]   Covid-19: risk factors for severe disease and death [J].
Jordan, Rachel E. ;
Adab, Peymane ;
Cheng, K. K. .
BMJ-BRITISH MEDICAL JOURNAL, 2020, 368
[10]   Fine particulate matter exposure during pregnancy and infancy and incident asthma [J].
Jung, Chau-Ren ;
Chen, Wei-Ting ;
Tang, Yu-Hsin ;
Hwang, Bing-Fang .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (06) :2254-+